D.E. Shaw & Co’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

D.E. Shaw & Co’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,871	Closed	-$70K	–	5907
2022 Q1	$70K	Buy	+1,871	New	+$64.7K	﹤0.01%	5064
2021 Q4	–	Sell	-2,240	Closed	-$162K	–	5794
2021 Q3	$162K	Sell	2,240 -659	-23%	-$50.4K	﹤0.01%	4619
2021 Q2	$278K	Sell	2,899 -1,913	-40%	-$211K	﹤0.01%	4316
2021 Q1	$711K	Buy	4,812 +2,754	+134%	+$499K	﹤0.01%	3329
2020 Q4	$288K	Buy	+2,058	New	+$333K	﹤0.01%	3615
2016 Q2	–	Sell	-130	Closed	-$167K	–	3584
2016 Q1	$167K	Buy	+130	New	+$185K	﹤0.01%	3224

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

D.E. Shaw & Co's NBSE Position: Q2 2022 in Review

D.E. Shaw & Co sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2022, closing a stake of 1,871 shares — an estimated $70K sold.

D.E. Shaw & Co first reported a position in NBSE in Q1 2016 and held it in 6 quarters. The position peaked at $711K in Q1 2021. 43 funds tracked by Wall St. Rank hold NBSE as of Q2 2022.

D.E. Shaw & Co reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
D.E. Shaw & Co sold 1,871 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $70K.
D.E. Shaw & Co first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2016 and held it in 6 quarters.
D.E. Shaw & Co's NeuBase Therapeutics, Inc. Common Stock position peaked at $711K in Q1 2021.
43 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.